Quality of life assessment in amyloid transthyretin (ATTR) amyloidosis.

ABSTRACT:

Background

Amyloid transthyretin (ATTR) amyloidosis is caused by the systemic deposition of transthyretin molecules, either normal (wild-type ATTR, ATTRwt) or mutated (variant ATTR, ATTRv). ATTR amyloidosis is a disease with a severe impact on patients' quality of life (QoL). Nonetheless, limited attention has been paid to QoL so far, and no specific tools for QoL assessment in ATTR amyloidosis currently exist. QoL can be evaluated through patient-reported outcome measures (PROMs), which are completed by patients, or through scales, which are compiled by clinicians. The scales investigate QoL either directly or indirectly, i.e., by assessing the degree of functional impairment and limitations imposed by the disease.

Design

Search for the measures of QoL evaluated in phase 2

SUBMITTER: Aimo A 

PROVIDER: S-EPMC8596396 | biostudies-literature | 2021 Nov

REPOSITORIES: biostudies-literature